Novo Nordisk's Oral Wegovy Wins FDA Approval, Beating Eli Lilly to Market
The FDA approved Novo Nordisk's oral formulation of Wegovy, making it the first obesity pill based on GLP-1 technology. The approval gives Novo a head start over rival Eli Lilly.